Echtzeit-Aktienkurs Kitov Pharma Ltd. (ADRs)
Bid:
Ask:
Echtzeit-Chart der Kitov Pharma Ltd. (ADRs) Aktie
Fundamentaldaten der Kitov Pharma Ltd. (ADRs) Aktie
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2019 [USD] | 1,00 Mio. | -5,70 Mio. | -5,87 Mio. | -0,30 | - | - | - |
| 2018 [USD] | 1,00 Mio. | -5,55 Mio. | -5,18 Mio. | -0,37 | - | - | - |
| 2017 [USD] | - | -13,11 Mio. | -12,37 Mio. | -1,21 | - | - | - |
| 2016 [USD] | - | -12,16 Mio. | -12,16 Mio. | -44,14 | - | - | - |
| 2015 [USD] | - | -4,20 Mio. | -4,20 Mio. | -87,97 | - | - | - |
| 2014 [USD] | - | -5,42 Mio. | -5,42 Mio. | -485,06 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Kitov Pharma Ltd. (ADRs) Aktie
Kitov Pharma Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack in June 2010 and is headquartered in Tel Aviv, Israel.